Basilea Pharmaceutica AG (BSLN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Basilea Pharmaceutica AG (BSLN) has a cash flow conversion efficiency ratio of 0.224x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF23.06 Million) by net assets (CHF103.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Basilea Pharmaceutica AG - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Basilea Pharmaceutica AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Basilea Pharmaceutica AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Basilea Pharmaceutica AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Bioperfectus Technologies Co Ltd
SHG:688399
|
0.007x |
|
Nexpoint Residential Trust Inc
NYSE:NXRT
|
0.020x |
|
Naphtha
TA:NFTA
|
0.097x |
|
Autobacs Seven Co.Ltd
F:AB6
|
N/A |
|
Beijing Career International Co Ltd
SHE:300662
|
0.059x |
|
BLACK DIAMOND GRP LTD
F:8B8
|
0.115x |
|
CeriBell, Inc
NASDAQ:CBLL
|
-0.069x |
|
Hanwha REIT Co. Ltd.
KO:451800
|
N/A |
Annual Cash Flow Conversion Efficiency for Basilea Pharmaceutica AG (2002–2024)
The table below shows the annual cash flow conversion efficiency of Basilea Pharmaceutica AG from 2002 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CHF81.00 Million | CHF74.36 Million | 0.918x | +164.47% |
| 2023-12-31 | CHF-10.00 Million | CHF14.24 Million | -1.424x | -318.08% |
| 2022-12-31 | CHF-20.71 Million | CHF7.06 Million | -0.341x | -162.35% |
| 2021-12-31 | CHF-58.61 Million | CHF-32.02 Million | 0.546x | +2.99% |
| 2020-12-31 | CHF-102.05 Million | CHF-54.13 Million | 0.530x | -22.75% |
| 2019-12-31 | CHF-92.96 Million | CHF-63.84 Million | 0.687x | -42.19% |
| 2018-12-31 | CHF-66.69 Million | CHF-79.21 Million | 1.188x | +358.87% |
| 2017-12-31 | CHF-41.44 Million | CHF19.01 Million | -0.459x | -121.41% |
| 2016-12-31 | CHF-35.00 Million | CHF-75.00 Million | 2.143x | +146.97% |
| 2015-12-31 | CHF14.86 Million | CHF-67.78 Million | -4.562x | -269.86% |
| 2014-12-31 | CHF57.93 Million | CHF-71.46 Million | -1.234x | -47.01% |
| 2013-12-31 | CHF70.87 Million | CHF-59.47 Million | -0.839x | -159.74% |
| 2012-12-31 | CHF105.50 Million | CHF148.17 Million | 1.404x | +361.31% |
| 2011-12-31 | CHF153.27 Million | CHF-82.38 Million | -0.537x | -205.96% |
| 2010-12-31 | CHF210.24 Million | CHF106.64 Million | 0.507x | +143.29% |
| 2009-12-31 | CHF97.73 Million | CHF-114.51 Million | -1.172x | -84.04% |
| 2008-12-31 | CHF199.74 Million | CHF-127.17 Million | -0.637x | -170.10% |
| 2007-12-31 | CHF335.10 Million | CHF-78.99 Million | -0.236x | +63.47% |
| 2006-12-31 | CHF112.31 Million | CHF-72.47 Million | -0.645x | -415.05% |
| 2005-12-31 | CHF167.87 Million | CHF34.38 Million | 0.205x | +166.86% |
| 2004-12-31 | CHF209.60 Million | CHF-64.20 Million | -0.306x | +47.24% |
| 2003-12-31 | CHF90.29 Million | CHF-52.42 Million | -0.581x | -13.63% |
| 2002-12-31 | CHF125.38 Million | CHF-64.07 Million | -0.511x | -- |
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus au… Read more